HLS Therapeutics Inc ( (TSE:HLS) ) has issued an announcement.
HLS Therapeutics reported a 5% increase in total product revenue for Q1 2025 compared to Q1 2024, with significant growth in the Canadian market driven by a 34% rise in Vascepa sales. The company also achieved a 41% increase in adjusted EBITDA, reflecting operational efficiencies and a 20% reduction in operating expenses. HLS expanded its cardiovascular portfolio by securing Canadian rights to NEXLETOL and NEXLIZET from Esperion Therapeutics, aligning with its strategic focus on growth and shareholder value enhancement. This expansion is expected to complement existing products and address unmet medical needs, with commercial launch preparations underway for early 2026.
Spark’s Take on TSE:HLS Stock
According to Spark, TipRanks’ AI Analyst, TSE:HLS is a Neutral.
HLS Therapeutics Inc demonstrates strong operational efficiency and cash management, despite persistent net losses affecting profitability. The stock shows positive momentum above key moving averages, but the lack of profitability and absence of a dividend yield weigh on its valuation. The recent addition to the board is a strategic positive, potentially enhancing the company’s market position.
To see Spark’s full report on TSE:HLS stock, click here.
More about HLS Therapeutics Inc
HLS Therapeutics Inc. is a pharmaceutical company dedicated to addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. The company focuses on expanding its product portfolio in the Canadian market, leveraging its established cardiovascular infrastructure.
Average Trading Volume: 10,669
Technical Sentiment Signal: Hold
Current Market Cap: C$138.3M
For detailed information about HLS stock, go to TipRanks’ Stock Analysis page.